R. Kanti

33.0k total citations · 11 hit papers
281 papers, 23.3k citations indexed

About

R. Kanti is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, R. Kanti has authored 281 papers receiving a total of 23.3k indexed citations (citations by other indexed papers that have themselves been cited), including 244 papers in Genetics, 122 papers in Pathology and Forensic Medicine and 120 papers in Immunology. Recurrent topics in R. Kanti's work include Chronic Lymphocytic Leukemia Research (242 papers), Lymphoma Diagnosis and Treatment (120 papers) and Immunodeficiency and Autoimmune Disorders (87 papers). R. Kanti is often cited by papers focused on Chronic Lymphocytic Leukemia Research (242 papers), Lymphoma Diagnosis and Treatment (120 papers) and Immunodeficiency and Autoimmune Disorders (87 papers). R. Kanti collaborates with scholars based in United States, United Kingdom and Italy. R. Kanti's co-authors include Nicholas Chiorazzi, Michael J. Keating, Manlio Ferrarini, Thomas J. Kipps, Laura Z. Rassenti, Steven L. Allen, Jonathan E. Kolitz, Peter Hillmen, Carlo M. Croce and Florencia Bullrich and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

R. Kanti

269 papers receiving 22.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia

2002 3.9k citations George A. Calin, Calin Dan Dumitru et al. Proceedings of the National Academy of Sciences profile →
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

2008 2.2k citations Michael J. Keating, R. Kanti et al. Blood profile →
Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia

1999 1.9k citations Rajendra N. Damle, Tarun Wasil et al. Blood profile →
Chronic Lymphocytic Leukemia

2005 1.3k citations Nicholas Chiorazzi, R. Kanti et al. New England Journal of Medicine profile →
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

2018 971 citations Michael J. Keating, Nicholas Chiorazzi et al. Blood profile →
Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia

2000 754 citations R. Kanti, Bercedis L. Peterson et al. New England Journal of Medicine profile →
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

2002 707 citations Michael J. Keating, R. Kanti et al. Blood profile →
Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors.

1998 690 citations Franco Fais, Fabio Ghiotto et al. Journal of Clinical Investigation profile →
ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia

2004 659 citations Laura Z. Rassenti, Michael J. Keating et al. New England Journal of Medicine profile →
Expression of Apoptosis-Regulating Proteins in Chronic Lymphocytic Leukemia: Correlations With In Vitro and In Vivo Chemoresponses

1998 534 citations Florencia Bullrich, R. Kanti et al. Blood profile →
Chronic lymphocytic leukaemia

2017 343 citations Carlo M. Croce, John G. Gribben et al. profile →

Peers

Countries citing papers authored by R. Kanti

Since Specialization

Citations

This map shows the geographic impact of R. Kanti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Kanti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Kanti more than expected).

Fields of papers citing papers by R. Kanti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Kanti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Kanti. The network helps show where R. Kanti may publish in the future.

Co-authorship network of co-authors of R. Kanti

This figure shows the co-authorship network connecting the top 25 collaborators of R. Kanti. A scholar is included among the top collaborators of R. Kanti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Kanti. R. Kanti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	128TiP: ABBIL1TY NSCLC-06: A global, randomized, open-label, phase III trial of acasunlimab in combination with pembrolizumab (Pembro) vs docetaxel in checkpoint inhibitor (CPI)-experienced patients with PD-L1+ metastatic non-small cell lung cancer (mNSCLC) 2025 ·Journal of Thoracic Oncology ·(unknown), (unknown), Michael Thomas, Joachim G.J.V. Aerts, (unknown), (unknown), James D’Olimpio, Kenta Kasahara, (unknown), R. Kanti, (unknown), Kyoung Un Park, (unknown), (unknown), Tomer M. Mark, Matteo Sacchi, (unknown)	0
2	Chronic lymphocytic leukemia often arises by a multiclonal selection process 2025 ·Haematologica ·Davide Bagnara, Andrea Nicola Mazzarello, (unknown), Stefano Vergani, Siddha Kasar, Stacey M. Fernandes, Gerardo Ferrer, Fabio Ghiotto, Jacqueline C. Barrientos, Jonathan E. Kolitz, R. Kanti, (unknown), Monica Colombo, Franco Fais, Jennifer R. Brown, Manlio Ferrarini, Nicholas Chiorazzi	0
3	BCL2 Protein Progressively Declines during Robust CLL Clonal Expansion: Potential Impact on Venetoclax Clinical Efficacy and Insights on Mechanism 2024 ·PubMed ·Hyunjoo Lee, Shabirul Haque, (unknown), Jonathan E. Kolitz, Steven L. Allen, R. Kanti, Nicholas Chiorazzi, Patricia K. A. Mongini	1
4	Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model 2023 ·Clinical Cancer Research ·Shih‐Shih Chen, Jacqueline C. Barrientos, Gerardo Ferrer, (unknown), (unknown), (unknown), Michael Ibrahim, (unknown), (unknown), Jeffery L. Kutok, (unknown), (unknown), David T. Weaver, Jonathan A. Pachter, R. Kanti, Nicholas Chiorazzi	5
5	Characterization of the Intraclonal Complexity of Chronic Lymphocytic Leukemia B Cells: Potential Influences of B-Cell Receptor Crosstalk with Other Stimuli 2023 ·Cancers ·Andrea Nicola Mazzarello, Mark Fitch, (unknown), (unknown), (unknown), (unknown), Davide Bagnara, Jonathan E. Kolitz, Jacqueline C. Barrientos, Steven L. Allen, R. Kanti, Joanna Rhodes, Marc K. Hellerstein, Nicholas Chiorazzi	2
6	Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL 2021 ·Leukemia ·Gerardo Ferrer, (unknown), (unknown), Rukhsana Aslam, Florencia Palacios, Andrea Nicola Mazzarello, Stefano Vergani, Davide Bagnara, Shih‐Shih Chen, Sophia Yancopoulos, Aliki Xochelli, Xiao‐Jie Yan, Jan A. Burger, Jacqueline C. Barrientos, Jonathan E. Kolitz, Steven L. Allen, Κώστας Σταματόπουλος, R. Kanti, Barbara Sherry, Nicholas Chiorazzi	37
7	AID overexpression leads to aggressive murine CLL and nonimmunoglobulin mutations that mirror human neoplasms 2021 ·Blood ·Pablo Elías Morande, Xiao‐Jie Yan, (unknown), (unknown), (unknown), (unknown), Cecilia Abreu, Martina Crispo, (unknown), Natalia Rego, (unknown), Stephen P. Methot, Florencia Palacios, (unknown), R. Kanti, Alejandro Buschiazzo, Javier M. Di Noia, Marcelo A. Navarrete, Nicholas Chiorazzi, Pablo Oppezzo	8
8	Musashi 2 influences chronic lymphocytic leukemia cell survival and growth making it a potential therapeutic target 2021 ·Leukemia ·Florencia Palacios, Xiao‐Jie Yan, Gerardo Ferrer, Shih‐Shih Chen, Stefano Vergani, Xuejing Yang, Jeffrey R. Gardner, Jacqueline C. Barrientos, (unknown), Richard Burack, Jonathan E. Kolitz, Steven L. Allen, Michael G. Kharas, Omar Abdel‐Wahab, R. Kanti, Nicholas Chiorazzi	18
9	Ibrutinib Combined with Obinutuzumab and CHOP (I-OCHOP) for Richter Transformation 2021 ·Blood ·Carlos López, (unknown), Joanna Rhodes, R. Kanti, Jacqueline C. Barrientos	1
10	Chronic Lymphocytic Leukemia 2020 ·Cold Spring Harbor Perspectives in Medicine ·Nicholas Chiorazzi, Shih‐Shih Chen, R. Kanti	42
11	CLL Stereotyped Subset #4 Igs Acquire Binding to Viable B Lymphocyte Surfaces By Somatic Mutations, Isotype Class Switching, and with the Prerequisite of IG Self-Association 2017 ·Blood ·Yan Liu, Rosa Catera, Chao Gao, Xiao‐Jie Yan, Steven L. Allen, Jonathan E. Kolitz, R. Kanti, Charles C. Chu, Ten Feizi, Κώστας Σταματόπουλος, Nicholas Chiorazzi	1
12	A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease 2011 ·Blood ·Davide Bagnara, Matthew Kaufman, Carlo Calissano, Sonia Marsilio, Piers Patten, Rita Simone, (unknown), Xiao‐Jie Yan, Steven L. Allen, Jonathan E. Kolitz, Sivasubramanian Baskar, Christoph Rader, Håkan Mellstedt, Hodjattallah Rabbani, Annette Lee, Peter K. Gregersen, R. Kanti, Nicholas Chiorazzi	145
13	Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712 2011 ·Journal of Clinical Oncology ·Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema, Bercedis L. Peterson, John G. Gribben, Vicki A. Morrison, R. Kanti, Richard A. Larson, John C. Byrd	102
14	Intraclonal Complexity in Chronic Lymphocytic Leukemia: Fractions Enriched in Recently Born/Divided and Older/Quiescent Cells 2011 ·Molecular Medicine ·Carlo Calissano, Rajendra N. Damle, Sonia Marsilio, Xiao‐Jie Yan, Sophia Yancopoulos, Gregory M. Hayes, Claire Emson, Elizabeth J. Murphy, Marc K. Hellerstein, Cristina Sison, Matthew Kaufman, Jonathan E. Kolitz, Steven L. Allen, R. Kanti, (unknown), Igor Dozmorov, Sergio Roa, Matthew D. Scharff, Wentian Li, Nicholas Chiorazzi	129
15	Introduction: Chronic lymphocytic leukemia in perspective 2007 ·Best Practice & Research Clinical Haematology ·R. Kanti	1
16	Pathophysiologic mechanisms of chronic lymphocytic leukemia and their application to therapy 2007 ·Experimental Hematology ·R. Kanti	7
17	In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells 2005 ·Journal of Clinical Investigation ·Bradley T. Messmer, Davorka Messmer, Steven L. Allen, Jonathan E. Kolitz, (unknown), Denise Cesar, Elizabeth J. Murphy, Prasad Koduru, Manlio Ferrarini, Simona Zupo, Giovanna Cutrona, Rajendra N. Damle, Tarun Wasil, R. Kanti, Marc K. Hellerstein, Nicholas Chiorazzi	21
18	Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia breakdown → 2002 ·Proceedings of the National Academy of Sciences ·George A. Calin, Calin Dan Dumitru, Masayoshi Shimizu, (unknown), Simona Zupo, Evan Noch, (unknown), (unknown), Michael J. Keating, R. Kanti, Laura Z. Rassenti, Thomas J. Kipps, Massimo Negrini, Florencia Bullrich, Carlo M. Croce	3875
19	Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed 2002 ·Journal of Clinical Oncology ·Michael J. Keating, Bruno Cazin, Steven Coutré, Ruemu Birhiray, Tibor Kovacsovics, Wolfgang Langer, Brian Leber, T.S. Maughan, R. Kanti, Geir E. Tjønnfjord, (unknown), M. Itzhaki, Patrice Herait	73
20	Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia breakdown → 2000 ·New England Journal of Medicine ·R. Kanti, Bercedis L. Peterson, Frederick R. Appelbaum, Jonathan E. Kolitz, Laurence Elias, Lois E. Shepherd, John Hines, Gregory A. Threatte, Richard A. Larson, Bruce D. Cheson, Charles A. Schiffer	754

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact